Bora Pharmaceuticals announced on March 23 that its Chungli facility has been officially approved by Taipei Customs as a Bonded Factory. This strategic designation allows the plant to import raw materials duty-free, deferring tax payments and optimizing customs clearance efficiency.

• Operational Leverage: This move is expected to enhance the synergy between Bora’s manufacturing networks in Taiwan and North America. For an export-oriented CDMO, bonded status reduces capital tie-up and shortens delivery lead times, strengthening global competitiveness.
• Supply Chain Synergy: Senior VP Chang Chen-tang noted that with rising order volumes, having both the Chungli and Zhunan plants under the bonded system allows for cross-plant coordination in container loading and shipping schedules, reducing logistics bottlenecks.
• North American Stability: Bora recently renewed a five-year, US$250 million global manufacturing contract with a key international client. The contract covers over 20 commercial product lines and 335 individual SKUs, primarily produced at its Canadian and U.S. oral drug facilities.
• Strategic Outlook: The improved capital efficiency in Taiwan, combined with the locked-in cash flow from North American long-term contracts, bolsters Bora’s bargaining power and order visibility in the global CDMO market.

Resource: 保瑞提升CDMO出口動能 中壢廠升格保稅工廠